clopidogrel

Last reviewed 04/2021

Clopidogrel is an anti-platelet drug, of the thienopyridine class, which is licensed for the secondary prophylaxis of atherosclerotic complications in patients with:

• ischaemic heart disease
• cerebrovascular disease
• peripheral vascular disease

The dose is 75 mg per day.

The principal side-effect is haemorrhage, including:

• gastrointestinal
• intracranial

There may be gastrointestinal upset.

Maximal inhibition of platelet aggregation is achieved after 4-7 days with clopidogrel 75 mg per day (1).

The summary of product characteristics should be consulted before prescribing this drug.

Reference:

1. Solet D et al. The role of adenosine 5'-diphosphate receptor blockade in patients with cardiovascular disease. Am J Med 2001;111:45-53.
2. Drug and Therapeutics Bulletin 1999; 37 (8): 59-61.
3. Factfile 12/98. Antithrombotic drugs. British Heart Foundation.